Tacrolimus (Advagraf®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000361
English
Authors' recommendations:
Tacrolimus (Advagraf®) is recommended as an option for restricted use within NHS Wales for the prophylaxis of transplant rejection in adult kidney or liver allograft recipients.
Tacrolimus (Advagraf®) is not recommended for use within NHS Wales for the treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.
Tacrolimus (Advagraf®) should be prescribed by brand name to reduce the risk of medication errors.
AWMSG is of the opinion that tacrolimus (Advagraf®) may be suitable for shared care for the above indication.
Details
Project Status:
Completed
Year Published:
2011
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=177679&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Graft Rejection
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.